Axogen, Inc. filed a Form 8-K on September 10, 2026, disclosing a $200.0 million merger agreement to acquire BioCircuit Technologies, Inc. and a concurrent public offering of common stock priced at $42.50 per share.
Key Highlights
- Merger price: The base purchase price for BioCircuit Technologies is $200.0 million in cash, subject to customary adjustments for cash, indebtedness, transaction expenses, and net working capital.
- BioCircuit's products: BioCircuit develops and commercializes its "NerveTape" and "ConformaWrap" products for repair of peripheral nerve discontinuities.
- Expected closing: The parties expect to complete the merger in the fourth quarter of 2026, with a termination right if the merger has not closed by December 31, 2026.
- Offering size: Axogen agreed to sell 4,910,000 shares of common stock at a public offering price of $42.50 per share, with the underwriters paying $39.95 per share.
- Overallotment option: The company granted underwriters a 30-day option to purchase up to an additional 736,500 shares of common stock.
- Funding obligation: The company has agreed to obtain sufficient funding to finance the transaction within 90 days of execution of the merger agreement, and failure to do so will constitute a breach.
- Post-closing holdback: At closing, $1.0 million will be withheld to satisfy any post-closing purchase price adjustments.
Axogen Enters Merger Agreement for BioCircuit and Prices Common Stock Offering
According to the filing, Axogen, Inc. (NASDAQ:AXGN) entered into an Agreement and Plan of Merger on September 9, 2026, with Omega Merger Sub, Inc., a wholly owned subsidiary of the company, BioCircuit Technologies, Inc., and Michelle Jarrard as the stockholders' representative. Under the terms disclosed, Merger Sub will merge with and into BioCircuit, with BioCircuit surviving as a wholly owned subsidiary of Axogen. The company reported that all outstanding equity securities of BioCircuit will be cancelled and converted into the right to receive the applicable portion of the merger consideration at the effective time of the merger.
The filing states that prior to closing, BioCircuit will spin out an unrelated electronics business to its stockholders, and all outstanding convertible promissory notes of BioCircuit must be converted into shares of BioCircuit common stock before closing. The merger is not expected to require any regulatory approvals, according to the filing. Closing conditions include consent under an inbound intellectual property license agreement and completion of the electronics business spin-out. The filing notes there is no termination fee in the event of termination, and the merger is not subject to a financing condition.
On September 10, 2026, the company entered into an underwriting agreement with BofA Securities, Inc., Jefferies LLC, and Wells Fargo Securities, LLC as representatives of the underwriters, the filing disclosed. The common stock is being offered under an effective shelf registration statement on Form S-3ASR (File No. 333-292852) filed with the SEC on January 21, 2026. The closing of the offering is expected to occur on September 11, 2026. The company disclosed it intends to use the net proceeds from the offering to finance the merger.
What Was Disclosed
Axogen disclosed a $200.0 million cash merger agreement to acquire BioCircuit Technologies and a concurrent public equity offering of 4,910,000 shares at $42.50 per share, with closing of both transactions expected in the fourth quarter of 2026.




Please wait processing your request...